Neuropharmacology
May 27, 2023
David J Heal, Sharon L. Smith, Sean J Belouin et al.
50 citations
This Special Issue of Neuropharmacology on psychedelics provides a timely and comprehensive update on progress following the previous Neuropharmacology Special Issue "Psychedelics: New Doors, Altered Perceptions". Remarkable advances have been made in basic and clinical research on psychedelics in the five years since 2018. It is partly based on the seminar series focused on psilocybin...
iScience
May 19, 2023
Andres Ort, John W Smallridge, Simone Sarasso et al.
47 citations
Exploring the neurobiology of the profound changes in consciousness induced by classical psychedelic drugs may require novel neuroimaging methods. Serotonergic psychedelic drugs such as psilocybin produce states of increased sensory-emotional awareness and arousal, accompanied by increased spontaneous electroencephalographic (EEG) signal diversity. By directly stimulating cortical tissue, the...
Heliyon
May 17, 2023
Dominique Strauss, Soumya Ghosh, Zurika Murray et al.
7 citations
Psychedelic fungi have received considerable attention recently due to their promising treatment potential of several psychiatric disorders and medical conditions, both in clinical settings but also as a nutraceutical. Besides research, a growing number of companies are developing capacity to conduct research and clinical trials where these fungi and their products can be used, and to provide...
PARIPEX INDIAN JOURNAL OF RESEARCH
May 15, 2023
Chirag Ambaliya, Dimple Gupta, Ashok Vala et al.
The purpose of this review article is to give a summary of the literature on the use of psychedelic drugs, such as psilocybin, LSD, ayahuasca, and MDMA, in the treatment of various mental health conditions, such as depression, anxiety, PTSD, and substance use disorders. This review's main goal is to highlight recent human studies on the use of particular psychedelic drugs, like psilocybin, LSD,...
bioRxiv (Cold Spring Harbor Laboratory)
May 12, 2023
S. Parker Singleton, Christopher Timmermann, Andrea I. Luppi et al.
18 citations
preprint
Psychedelics offer a profound window into the functioning of the human brain and mind through their robust acute effects on perception, subjective experience, and brain activity patterns. In recent work using a receptor-informed network control theory framework, we demonstrated that the serotonergic psychedelics lysergic acid diethylamide (LSD) and psilocybin flatten the brain's control energy...
Frontiers in Psychiatry
May 12, 2023
Grace Blest‐hopley, Ben H Amit, Aisling O'Neill et al.
Editorial on the Research Topic Appropriateness and safety of using cannabinoid and psychedelic medicines as treatments for psychiatric disorders
Medicina
May 9, 2023
Gniewko Więckiewicz, Julia Marek, Iga Stokłosa et al.
5 citations
Background and Objectives: PolDrugs is the largest Polish naturalistic nationwide survey to present basic demographic and epidemiological data that could potentially prevent harm from illicit substances intake in drugs users. The most recent results were presented in 2021. The goal of this year’s edition was to re-present the above data and compare it to the previous edition’s data to identify...
Journal of Affective Disorders
May 1, 2023
Guy M. Goodwin, Megan Croal, Lindsey Marwood et al.
13 citations
Blinding of treatment allocation in clinical trials in psychiatry is regarded as an ideal. The potential impact of unblinding chimes with a general concern for psychological research: so-called demand characteristics can undermine confidence in findings from experimental and clinical studies. Scepticism can result in nihilism. The reliance on subjective report of symptoms in clinical trials of...
May 1, 2023
Hiroyuki Uchida
1 citation
In recent years, it is common for a single drug to be developed for multiple diseases almost simultaneously, e.g., pimavanserin and psilocybin. Although there was gloomy news for the field of neuropsychopharmacology, such as withdrawal of the world's leading mega-pharmaceutical companies from the development of CNS drugs, drugs based on novel mechanisms of action have been investigated. This is...
Frontiers in Neuroscience
April 17, 2023
Marvin M. Urban, Moritz R. Stingl, Marcus W. Meinhardt
47 citations
The potential of psychedelics to persistently treat substance use disorders is known since the 1960s. However, the biological mechanisms responsible for their therapeutic effects have not yet been fully elucidated. While it is known that serotonergic hallucinogens induce changes in gene expression and neuroplasticity, particularly in prefrontal regions, theories on how specifically this...